Literature DB >> 33421988

Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection.

Himanshu Garg1, Rose Yeh2, Douglas M Watts3, Tugba Mehmetoglu-Gurbuz4, Robert Resendes5, Bruce Parsons5, Fernando Gonzales5, Anjali Joshi6.   

Abstract

BACKGROUND: Recent outbreaks of Zika Virus (ZIKV) infection and associated microcephaly has raised multiple scientific questions. The close antigenic relatedness between flaviviruses makes diagnosis of specific infection difficult. This relatedness also raises the potential of Antibody Dependent Enhancement (ADE) via cross reactive antibodies to flaviviruses like West Nile Virus (WNV) and Dengue Virus (DENV). Asymptomatic WNV infections are endemic throughout the US creating a large proportion of the population that is seropositive for WNV antibodies. Whether these sero-positive individuals potentially carry ZIKV enhancing antibodies remains unknown.
RESULTS: Serum samples obtained from human subjects with symptomatic or asymptomatic WNV infection from a WNV endemic region in Texas were tested for their ability to enhance or neutralize ZIKV infection. Sero-surveillance data demonstrated a ~ 7% prevalence for WNV antibodies in the population. Sera from both symptomatic and asymptomatic WNV seropositive donors effectively neutralized WNV and to some extent DENV infection. Interestingly, WNV+ sera failed to inhibit ZIKV while significantly enhancing infection. Conversely, ZIKV specific sera effectively neutralized ZIKV, with ADE only evident at lower concentrations. The enhancement of ZIKV via WNV antibody positive sera was likely due to non-neutralizing Envelope (E) antibodies as seen with monoclonal ZIKV E antibodies.
CONCLUSIONS: Overall, our findings suggest that WNV antibodies in the sera significantly enhance ZIKV infection in Fc receptor positive cells with limited neutralization activity. Further studies in more relevant models of ADE will be needed to confirm the relevance of these findings in vivo.

Entities:  

Keywords:  ADE; DENV, neutralization; Enhancement; Envelope; WNV; ZIKV

Mesh:

Substances:

Year:  2021        PMID: 33421988      PMCID: PMC7796652          DOI: 10.1186/s12865-020-00389-2

Source DB:  PubMed          Journal:  BMC Immunol        ISSN: 1471-2172            Impact factor:   3.615


  52 in total

1.  Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981.

Authors:  G P Kouri; M G Guzmán; J R Bravo; C Triana
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

2.  A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells.

Authors:  Eiji Konishi; Yuko Tabuchi; Atsushi Yamanaka
Journal:  J Virol Methods       Date:  2009-10-31       Impact factor: 2.014

3.  Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.

Authors:  Scott A Smith; Usha K Nivarthi; Ruklanthi de Alwis; Nurgun Kose; Gopal Sapparapu; Robin Bombardi; Kristen M Kahle; Jennifer M Pfaff; Sherri Lieberman; Benjamin J Doranz; Aravinda M de Silva; James E Crowe
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

4.  Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity.

Authors:  Susana V Bardina; Paul Bunduc; Shashank Tripathi; James Duehr; Justin J Frere; Julia A Brown; Raffael Nachbagauer; Gregory A Foster; David Krysztof; Domenico Tortorella; Susan L Stramer; Adolfo García-Sastre; Florian Krammer; Jean K Lim
Journal:  Science       Date:  2017-03-30       Impact factor: 47.728

5.  Dengue Virus-Specific Antibodies Enhance Brazilian Zika Virus Infection.

Authors:  Priscila M S Castanha; Eduardo J M Nascimento; Cynthia Braga; Marli T Cordeiro; Otávio V de Carvalho; Leila R de Mendonça; Elisa A N Azevedo; Rafael F O França; Rafael Dhalia; Ernesto T A Marques
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

6.  Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.

Authors:  Himanshu Garg; Melina Sedano; Gabrielle Plata; Erin B Punke; Anjali Joshi
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

7.  Zika virus outbreak on Yap Island, Federated States of Micronesia.

Authors:  Mark R Duffy; Tai-Ho Chen; W Thane Hancock; Ann M Powers; Jacob L Kool; Robert S Lanciotti; Moses Pretrick; Maria Marfel; Stacey Holzbauer; Christine Dubray; Laurent Guillaumot; Anne Griggs; Martin Bel; Amy J Lambert; Janeen Laven; Olga Kosoy; Amanda Panella; Brad J Biggerstaff; Marc Fischer; Edward B Hayes
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

Review 8.  A Tale of Two Viruses: Does Heterologous Flavivirus Immunity Enhance Zika Disease?

Authors:  Carlos A Sariol; Mauricio L Nogueira; Nikos Vasilakis
Journal:  Trends Microbiol       Date:  2017-11-06       Impact factor: 17.079

Review 9.  The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis.

Authors:  Thomas Langerak; Noreen Mumtaz; Vera I Tolk; Eric C M van Gorp; Byron E Martina; Barry Rockx; Marion P G Koopmans
Journal:  PLoS Pathog       Date:  2019-04-18       Impact factor: 6.823

10.  Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population.

Authors:  Mayra R Montecillo-Aguado; Alfredo E Montes-Gómez; Julio García-Cordero; Josselin Corzo-Gómez; Héctor Vivanco-Cid; Gabriela Mellado-Sánchez; J Esteban Muñoz-Medina; Benito Gutiérrez-Castañeda; Leopoldo Santos-Argumedo; César González-Bonilla; Leticia Cedillo-Barrón
Journal:  J Immunol Res       Date:  2019-09-02       Impact factor: 4.818

View more
  3 in total

Review 1.  The Role of Antibodies in the Treatment of SARS-CoV-2 Virus Infection, and Evaluating Their Contribution to Antibody-Dependent Enhancement of Infection.

Authors:  Mohammed A H Farouq; Reinaldo Acevedo; Valerie A Ferro; Paul A Mulheran; Mohammed M Al Qaraghuli
Journal:  Int J Mol Sci       Date:  2022-05-28       Impact factor: 6.208

2.  Dynamics of the Magnitude, Breadth and Depth of the Antibody Response at Epitope Level Following Dengue Infection.

Authors:  Francesca Falconi-Agapito; Karen Kerkhof; Xiomara Merino; Johan Michiels; Marjan Van Esbroeck; Koen Bartholomeeusen; Michael Talledo; Kevin K Ariën
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

3.  Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara.

Authors:  Nereida Jiménez de Oya; Patricia Pérez; Ana-Belén Blázquez; Estela Escribano-Romero; Mariano Esteban; Juan-Carlos Saiz; Juan García-Arriaza; Miguel A Martín-Acebes
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.